Lipocine (LPCN) Given Media Sentiment Score of 0.10
Media stories about Lipocine (NASDAQ:LPCN) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lipocine earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.8598944170107 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Lipocine Inc. (LPCN) Issues Earnings Results (americanbankingnews.com)
- BRIEF-Lipocine posts Q2 loss per share $0.31 (reuters.com)
- Lipocine Inc. (LPCN) PT Set at $11.00 by Canaccord Genuity (americanbankingnews.com)
- Bulls&Bears Captivating in Wall Street: Lipocine Inc. (NASDAQ:LPCN) – NASDAQ Times (nasdaqtimes.com)
- Lipocine Inc (LPCN) A Look Inside the Technicals – Sparta Review (spartareview.com)
Shares of Lipocine (NASDAQ LPCN) traded up 0.67% during trading on Tuesday, hitting $4.52. The company had a trading volume of 124,850 shares. Lipocine has a 1-year low of $3.03 and a 1-year high of $5.90. The firm’s market capitalization is $87.06 million. The company’s 50 day moving average is $4.42 and its 200 day moving average is $3.97.
Lipocine (NASDAQ:LPCN) last posted its earnings results on Monday, August 7th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. Analysts anticipate that Lipocine will post ($1.12) earnings per share for the current fiscal year.
A number of research firms have issued reports on LPCN. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Lipocine in a report on Wednesday, April 26th. Canaccord Genuity set a $11.00 price target on Lipocine and gave the stock a “buy” rating in a report on Monday. Finally, Roth Capital set a $38.00 price target on Lipocine and gave the stock a “buy” rating in a report on Tuesday, June 20th.
TRADEMARK VIOLATION NOTICE: “Lipocine (LPCN) Given Media Sentiment Score of 0.10” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/08/lipocine-lpcn-given-media-sentiment-score-of-0-10.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.